[1]
|
Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 1985, 228(4705): 1315-1317. doi: 10.1126/science.4001944 |
[2]
|
Kehoe JW, Kay BK. Filamentous phage display in the new millennium. Chem Rev, 2005, 105(11): 4056-4072. doi: 10.1021/cr000261r |
[3]
|
Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol, 1997, 15(6): 542-546. doi: 10.1038/nbt0697-542 |
[4]
|
Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol, 2009, 27(4): 331-337. doi: 10.1038/nbt0409-331 |
[5]
|
Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol, 2008, 9(6): 423-430. doi: 10.2174/138920108786786358 |
[6]
|
Wiiger MT, Gehrken HB, Fodstad O, et al. A novel human recombinant single-chainan tibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother, 2010, 59(11): 1665-1674. doi: 10.1007/s00262-010-0892-3 |
[7]
|
Lamoureux F, Trichet V, Chipoy C, et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther, 2007, 7(2): 169-181. doi: 10.1586/14737140.7.2.169 |
[8]
|
Scotlandi K, Picci P, Kovar H. Targeted therapies in bone sarcomas. Curr Cancer Drug Targets, 2009, 9(7): 843-853. doi: 10.2174/156800909789760410 |
[9]
|
Seung-Min L, Gil-Suk Y, Eun-Sang Y, et al. Application of phage display to discovery of tumor-specific homing peptides: developing strategies for therapy and molecular imaging of cancer. Methods Mol Biol, 2009, 512: 355-363. |
[10]
|
Jayanna PK, Bedi D, Deinnocentes P, et al. Landscape phage ligands for PC3 prostate carcinoma cells. Protein Eng Des Sel, 2010, 23(6): 423-430. doi: 10.1093/protein/gzq011 |
[11]
|
EnbackJ, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans, 2007, 35(Pt 4): 780-783. |
[12]
|
Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci, 2009, 14: 887-899. |
[13]
|
Niu G, Chen X. PET Imaging of Angiogenesis. PET Clin, 2009, 4(1): 17-38. doi: 10.1016/j.cpet.2009.04.011 |
[14]
|
Sun X, Niu G, Yan Y, et al. Phage display-derived peptides for osteosarcoma imaging. Clin Cancer Res, 2010, 16(16): 4268-4277. doi: 10.1158/1078-0432.CCR-10-0968 |
[15]
|
Zhang CL, Wang RF, Zhang L, et al. 131I labeling and bioactivity evaluation of a novel RGD dimer targeted to integrin alphavbeta3 receptor. Beijing Da Xue Xue Bao, 2011, 43(2): 295-300. |
[16]
|
LeungK. 68Ga-1, 4, 7-triazacyclononane-1, 4-7-triacetic acidisothiocyanatobenzyl-c(Arg-Gly-Asp-d-Tyr-Lys)[DB/OL]. Bethesda(MD): National Center for Biotechnology Information(US), 2011-01-26(2011-04-07). http://www.ncbi.nlm.nih.gov/books/NBK53807. |
[17]
|
Liu Z, Shi J, Jia B, et al. Two(90)Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy. Mol Pharm, 2011, 8(2): 591-599. doi: 10.1021/mp100403y |
[18]
|
Del Valle L, Enam S, Lassak A, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res, 2002, 8(6): 1822-1830. |
[19]
|
Runnels HA, Arbuckle JA, Bailey KS, et al. Human monoclonalantibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies. Adv Ther, 2010, 27(7): 458-475. doi: 10.1007/s12325-010-0026-5 |
[20]
|
van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule(ALCAM)ALCAMinteraction. J Biol Chem, 2001, 276(28): 25783-25790. doi: 10.1074/jbc.M011272200 |
[21]
|
Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: anew paradox in cancer. Transl Res, 2008, 151(3): 122-128. doi: 10.1016/j.trsl.2007.09.006 |
[22]
|
Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279(5349): 377-380. doi: 10.1126/science.279.5349.377 |
[23]
|
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature, 2000, 408(6810): 307-310. doi: 10.1038/35042675 |
[24]
|
Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol, 2007, 8(4): 275-283. doi: 10.1038/nrm2147 |
[25]
|
Liu M, Li C, Pazgier M, et al. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. ProcNatlAcadSciUSA, 2010, 107(32): 14321-14326. doi: 10.1073/pnas.1008930107 |
[26]
|
Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci, 2007, 120(Pt 3): 371-378. |
[27]
|
Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 1992, 69(7): 1237-1245. doi: 10.1016/0092-8674(92)90644-R |
[28]
|
Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBSLett, 1997, 420(1): 25-27. doi: 10.1016/S0014-5793(97)01480-4 |
[29]
|
de Graaf P, Little NA, Ramos YF, et al. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem, 2003, 278(40): 38315-38324. doi: 10.1074/jbc.M213034200 |
[30]
|
Linares LK, Hengstermann A, Ciechanover A, et al. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA, 2003, 100(21): 12009-12014. doi: 10.1073/pnas.2030930100 |
[31]
|
Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell, 2006, 127(7): 1323-1334. doi: 10.1016/j.cell.2006.12.007 |
[32]
|
Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445(7128): 661-665. doi: 10.1038/nature05541 |
[33]
|
Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 2007, 445(7128): 656-660. doi: 10.1038/nature05529 |
[34]
|
Brown CJ, Lain S, Verma CS. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer, 2009, 9(12): 862-873. doi: 10.1038/nrc2763 |
[35]
|
Murray JK, Gellman SH. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers, 2007, 88(5): 657-686. doi: 10.1002/bip.20741 |
[36]
|
Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA, 2008, 105(10): 3933-3938. doi: 10.1073/pnas.0708917105 |
[37]
|
Pazgier M, Liu M, Zou G, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA, 2009, 106(12): 4665-4670. doi: 10.1073/pnas.0900947106 |
[38]
|
Liu M, Pazgier M, Li C, et al. A left-handed solution to peptide inhibition of the p53-MDM2 interaction. Angew Chem Int Ed Engl, 2010, 49(21): 3649-3652. doi: 10.1002/anie.201000329 |